[ad_1]
ORPHAN / SWEDISH (OTCMKTS: SWTUY) to from an expectation The score assigned to a purchase note in a research report published on Thursday, July 19
Separately, Zacks Investment Research lowered SWEDISH ORPHAN / S from a rating of 39, buy at a sales note in a research note on Wednesday, April 25. The shares of SWEDISH ORPHAN / S were opened Thursday at $ 27.45, reports Marketbeat.com, the lowest level in 52 weeks of 12, US $ 55 and a high of $ 52.76 in 52 weeks P / E ratio of 42.23, a PEG ratio of 3.43 and a beta of 1.29 The company has a current ratio of 1.89, a quick ratio of 1.46 and a debt ratio of 0.23
SWEDISH ORTHESE / S (OTCMKTS: SWTUY) last announced its quarterly results on Thursday, April 26.The company has reported $ 0.24 earnings per share for the quarter, beating Tho's consensus estimate of $ 0.17 per $ 0.07. SWEDISH ORPHAN / S recorded a return on equity of 22.20% and a net margin of 20.48%. The company achieved a turnover of $ 242.19 million for the quarter, compared with $ 218.76 million for analysts. The sell-side analysts predict that SWEDISH ORPHAN / S will show 1.08 EPS for the current year.
Company Profile SWEDISH ORPHAN / S
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures and sells pharmaceuticals in the therapeutic areas of biotechnology. Haemophilia, inflammation and genetic and lysosomal diseases. The company offers Elocta to treat hemophilia A; and Alprolix to treat hemophilia B.
Featured Article: What Does the Relative Strength Index Mean?
To view ValuEngine's full report, visit ValuEngine's official website. / S Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for SWEDISH ORPHAN / S and affiliates with MarketBeat.com's free daily newsletter.
Source link
